gefitinib has been researched along with naphthoquinones in 4 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (naphthoquinones) | Trials (naphthoquinones) | Recent Studies (post-2010) (naphthoquinones) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 7,110 | 149 | 2,923 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chow, LW; Fan, XX; Jiang, ZB; Leung, EL; Li, X; Liu, L; Loo, WT; Yao, XJ | 1 |
| Chen, JY; Jiang, Z; Long, F; Ren, YG; Tang, JC; Zhao, J | 1 |
| Ding, K; Hu, X; Li, QY; Li, YL; Lin, NM; Tan, BQ; Wang, F; Zhang, B; Zhang, C | 1 |
| Guo, J; Lu, B; Lv, H; Sun, Y; Wang, Q; Yu, J; Zhang, Y; Zhou, Q | 1 |
4 other study(ies) available for gefitinib and naphthoquinones
| Article | Year |
|---|---|
Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mutation; Naphthoquinones; Neoplasm Recurrence, Local; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Thioredoxin-Disulfide Reductase | 2017 |
Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Naphthoquinones; Quinazolines; Signal Transduction; Sincalide; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2018 |
Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lithospermum; Lung Neoplasms; Mice, Nude; Naphthoquinones; Protein Kinase Inhibitors; Reactive Oxygen Species | 2018 |
STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Mutation; Naphthoquinones; Neoplasm Invasiveness; Protein Kinase Inhibitors; Receptor Tyrosine Kinase-like Orphan Receptors; Signal Transduction; STAT3 Transcription Factor; Tumor Suppressor Protein p53 | 2021 |